Cargando…
Does nivolumab combined with fluorouracil-based chemotherapy produce higher objective response rate than other immunochemotherapy regimes in metastatic esophageal cancer?: authors reply
Autores principales: | Gao, Zhen, Huang, Shujie, Wang, Sichao, Tang, Dezhao, Xu, Wei, Zeng, Ruijie, Qiao, Guibin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10585616/ https://www.ncbi.nlm.nih.gov/pubmed/37868211 http://dx.doi.org/10.1016/j.lanwpc.2023.100927 |
Ejemplares similares
-
Does nivolumab combined with fluorouracil-based chemotherapy produce higher objective response rate than other immunochemotherapy regimes in metastatic esophageal cancer?
por: Li, Ying, et al.
Publicado: (2023) -
Efficacy and safety of immunochemotherapy, immunotherapy, chemotherapy, and targeted therapy as first-line treatment for advanced and metastatic esophageal cancer: a systematic review and network meta-analysis
por: Gao, Zhen, et al.
Publicado: (2023) -
Esophageal Stricture Following Radiation, Concurrent Immunochemotherapy, Treated With Hyperbaric Oxygen and Dilation
por: Ajayi, Olayinka D., et al.
Publicado: (2019) -
Conversion Surgery Following Immunochemotherapy in Initially Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma—A Real-World Multicenter Study (RICE-Retro)
por: Huang, Shujie, et al.
Publicado: (2022) -
Current trends of anticancer immunochemotherapy
por: Vacchelli, Erika, et al.
Publicado: (2013)